CoChat

Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

Bisphosphonate inhibition of bone resorption was proposed to be due to osteoclast apoptosis. We tested this hypothesis for both the N-containing bisphosphonates alendronate and risedronate, which inhibit farnesyldiphosphate synthase and thus protein isoprenylation, and for clodronate and etidronate, which are metabolized to adenosine triphosphate (ATP) analogs. We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number. At an N-bisphosphonate dose that inhibited resorption and induced apoptosis, the antiapoptotic caspase inhibitor, Z-VAD-FMK, maintained osteoclast (Oc) number but did not prevent inhibition of resorption. Furthermore, when cells were treated with either alendronate alone or in combination with Z-VAD-FMK for 24 or 48 h, subsequent addition of geranylgeraniol, which restores geranylgeranylation, returned bone resorption to control levels. On the other hand, Z-VAD-FMK did block etidronate and clodronate inhibition of resorption. Moreover, in cells treated with etidronate, but not alendronate or risedronate, Z-VAD-FMK also prevented actin disruption, an early sign of osteoclast inhibition by bisphosphonates. These observations indicate that, whereas induction of apoptosis plays a major role in etidronate and clodronate inhibition of resorption, alendronate and risedronate suppression of bone resorption is independent of their effects on apoptosis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s8756-3282(01)00615-9

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. Benford, 1999, Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates, Mol Pharmacol, 56, 131, 10.1124/mol.56.1.131 · doi:10.1124/mol.56.1.131 · Paper page

Cited by

See all 206

Metadata

Authors
Halasy-Nagy, J. M., Rodan, G. A., & Reszka, A. A.
Corresponding author
Reszka, A.A.
Venue
Bone
Publisher
Elsevier BV
Published
2001-12
Volume
29
Issue
6
Pages
553-559
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W2024098071
Cited by
190
References
39
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 9 · 2015: 5 · 2014: 9 · 2013: 8 · 2012: 11
FWCI
4.77
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
bisphosphonates, alendronate, risedronate, etidronate, clodronate, bone resorption, osteoclast apoptosis, osteoclast number, farnesyl diphosphate synthase, isoprenylation, geranylgeranylation, geranylgeraniol, caspase inhibition, z-VAD-fmk, ATP analogs
MeSH terms
Risedronic Acid, Actins, Animals, Bone Resorption, Cytoskeleton, Osteoclasts, Etidronic Acid, Apoptosis, Alendronate, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. https://app.cochat.ai/papers/10.1016/s8756-3282(01)00615-9
The paper
Halasy-Nagy, J. M., Rodan, G. A., & Reszka, A. A. (2001). Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. https://doi.org/10.1016/s8756-3282(01)00615-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.